US NUCLEAR REGULATORY COMMISSION APPROVED BY OME 3150-0120 Expres \$ 31-47

APPLICATION FOR MATERIAL LICENSE

INSTRUCTIONS SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

PEDERAL AGENCIES FILE APPLICATIONS WITH

U.S. NUCLEAR REGULATORY COMMISSION DIVISION OF FUEL CYCLE AND MITERIAL SAFETY, NMSS WASHINGTON, DC 70555

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS, IF YOU ARE

CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MASSACHUSETTS, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, BEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION I NUCLEAR MATERIAL SECTION 8 631 PARK AVENUE KING OF PRUSSIA PA 19406

ALABAMA, PLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO.

U.S. NUCLEAR REGULATORY COMMISSION, REGION II MATERIAL RADIATION PROTECTION SECTION 101 MARIETTA STREET, SUITE 2900 ATLANTA, GA 30323

IF YOU ARE LOCATED IN

ILLINGIS, INDIANA, IONA, MICHIGAN, MINISSOTA, MISSOURI, ONIO, OR WISCONSIN, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION III MATERIALS LICENSING SECTION 799 ROOSEVELT ROAD GLEN ELLYN, IL 40137

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, BOUTH DAKOTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV MATERIAL RADIATION PROTECTION SECTION 611 RYAN PLAZA DRIVE, SUITE 1000 ARLINGTON, TX. 76011

ALASKA ARIZONA CALIFORNIA HAWAII NEVADA OREGON WASHINGTON. AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION V MATERIAL RADIATION PROTECTION SECTION 1450 MARIA LANE, SUITE 210 WALNUT CREEK, CA. \$4556.

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION

1. THIS IS AN APPLICATION FOR (Check appropriate item)	2 NAME AND MAILING ADDRESS OF APPLICANT (INClude 20 Code)		
A NEW LICENSE	Maui Memorial Hospital		
X & AMENOMENT TO LICENSE NUMBER 53-13519-01	Radioisotope Service		
C RENEWAL OF LICENSE NUMBER	221 Mahalani St.		
	Wailuku, Maui, Hi. 96793		
3. ADDRESSIES WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED (Same as 2.)			
A NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION	TELEPHONE NUMBER		
James Bendon, M.D., RSO	(803) 242-2052		
SUBMIT ITEMS & THROUGH 11 ON BY A 11 PAPER. THE TYPE AND SCOPE OF INFORMAT	TION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GLUDS		
5. RADIOACTIVE MATERIAL	The state of the s		
 Element and mass number, b. chemical and/or physical form, and c. maximum amount which will be possessed at any one time. 	6. PURPOSEISI FOR WHICH LICENSED MATERIAL WILL BE USED.		
7. INDIVIDUALISI RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE	8 TRAINING FOR INDIVIOUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.		
* FACILITIE 8512020596 851001 REG5 LIC30 53-13519-01 PDR	10. RADIATION SAFETY PROGRAM		
11. WASTE WA 53-13519-01 PDR	12 LICENSEE FEES (See 10 CFR 170 and Section 170 31) FEE CATEGORY 7C AMOUNT ENCLOSED \$ EXEMPT		
THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF PREPARED IN CONFORMITY WITH TITLE 10. CODE OF FEDERAL REGULATIONS PAILS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF WARNING. 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT, 249 MAKES IT A TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER W	MTS 30, 32, 13, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN.		
SIGNATURE -CERTIFYING OFFICER TYPED/FRINTED NAME	17/7LE DATE		
Jerry Walker	Administrator 7/15/35		
S250K S1M-3 5M ENUMBER OF EMPLOYEES (Focultor S250K S1M-3 5M S250K-500K S3 5M-7M S500K-750K S7M-10M E NUMBER OF BEDS	Y ECONOMIC DATA If WOULD YOU BE WILLING TO FURNISH COST INFORMATION (Joiler and/or east hours) ON THE ECONOMIC IMPACT OF CURRENT NRC REGULATIONS OR ANY FUTURE FROPOSED NRC REGULATIONS THAT MAY AFFECT YOU? (NRC requieriors permit It to protect confidences commercial or financial-prograteryinformation furnished to the agency in confidences.)		
\$750K-1M >510M	718		
The state of the s	IC USE ONLY		
TYPE OF FEE FEE LOG FEE CATEGORY TOWNENTS	TAPPROVED BY		
AMOUNT RECEIVED TOHECK NUMBER	G1/L /		
	170,11(a)(9) //29/85 0		
PRIVACY ACT STATEMENT ON THE REVERSE	70188 70228		

LICENSED MATERIAL

ITEM 5 - Radioactive Material

Element and mass number: I-125

Chemical and/or physical form: Sealed source (AECL C-253 source in AECL C-236 source holder)

Maximum amount which will be possessed: 3 sources at 500 mCi per source

ITEM 6 - Purposes for Which Licensed Material Will Be Used

Use in OsteoAnalyzer Model No. SPSHA110, a bone mineral analyzer, for general medical use. The OsteoAnalyzer Model No. SPSHA110 has Certificate No. NR-525-D-101-S from the NRC Registry of Radioactive Sealed Sources and Devices.

ITEM 7 - Individual Responsible for Radiation Safety Program and Their Training and Experience.

James Bendon, M.D., RSO: Dr. Bendon has been authorized for use of materials listed in Item 6 of license number 53-13519-01 for uses in groups I, II, III, in vitro studies, & Kel33. Training and experience information is contained in the amendment application dated 4/30/80.

TRAINING AND EXPERIENCE

The following individuals will be Authorized Users. These are as per License No. 53-13519-01.

Eugene Wasson, III, M.D.

Groups I. II. III. IV and V
In vitro studies
Xenon 133
Strontium 90 ophthalmic applicator

James Bendon, N.D.

Groups I. II. and III In <u>vitro</u> studies Xenon 133

Thomas Abram. M.D.

Groups I. II. III
Iodine 131 as iodide for treatment
of hyperthyroidism. cardiac
dysfunction, or thyroid carcinoma
Phosphorus 32 as soluble phosphate
for treatment of polycythemia
vera. leukemia and bone metastases
In vitro studies
Xenon 133

David Joseph Heeney, M.D.

Groups I. II. and III
Iodine 131 as iodide for treatment
of hyperthyroidism, cardiac
dysfunction, or thyroid carcinoma
In vitro studies
Xenon 133

George Boren, 1.0.

As authorized by present amendment application.

INSTRUMENTATION

Survey Instrument

Type: A low-level survey meter capable of detecting 0.1 mR/hr to perform radiation surveys.

Model: Bicron Surveyor 200 or equivalent.

Diagnostic Instrument

Type: Bone mineral analyzer; also know as bone densitometer.

Model: OsteoAnalyzer Model SPSHAllO bone mineral analyzer for performing diagnostic studies.

RADIATION SAFETY PROGRAM

ITEM 10 - Radiation Safety Program

1. SURVEY PROGRAM

- 1.1. The use of the sealed source in the bone mineral analyzer consists of placing the source in a fixed geometry position in the analyzer. Once it is in place, the shielding and beam direction cannot change unless the analyzer suffers some damage.
- 1.2. A radiation survey shall be performed on the bone mineral analyzer for each new source that is placed in the machine. The results of the survey shall be documented.
- 1.3. A radiation survey shall be performed in the storage area each time an additional source in placed in the storage area for long term storage. The results of these surveys shall be documented.

2. RECORDS MANAGEMENT PROGRAM

- Records of radiation surveys of the bone mineral analyzer and the storage area shall be kept for five years.
- 2.2. Records of source receipt and transfer shall be kept for at least five years.
- 2.3 Records of leak tests of sealed sources shall be kept for at least five years.
- 2.4. Records of personnel exposure shall be kept indefinitely.
- 2.5. Records of source disposals shall be kept indefinitely.
- 2.6. Records shall be reviewed for completeness and accuracy semi-annually by the Radiation Safety Officer or his designate.

3. LEAK TEST PROCEDURES

3.1. Leak tests shall be performed on sources in use every six months. The leak tests shall be able to detect 0.005 uCi of activity. Results of the leak tests shall be documented. Leak tests shall be performed according to the following procedures:

- 3.1.1. Take a canvas wipe and wipe it around the joint between the source holder and source cap. Place the wipe in the folded paper envelope used to hold it.
- 3.1.2. Calibrate the laboratory counter with a mock iodine source. Count the mock iodine source for one minute.
- 3.1.3. Count background for one minute. Calculate the conversion factor for the detector as follows:

3.1.4. Remove the source and take a one minute background count. Calculate the minimum detectable activity (MDA) and minimum detectable count rate (MDCR) according to the following formulas:

MDCR = 1.64 x 2 x
$$C_b$$

MDA = K x 1.64 x 2 x C_b

- 3.1.5. Count the wipe for 1 minute. If the measured count rate is less than MDCR, record the activity as <MDA. If the measured count rate is greater than MDCR, calculate and record the actual activity.
- 3.1.6. With typical counting equipment, this counting procedure will result in a MDA of less than 0.0005 uCi.
- 4. INSTRUCTION TO PERSONNEL
- 4.1. Personnel who use the I-125 sealed sources in the OsteoAnalyzer will either be specifically authorized by the license, or will have completed the in-house training program for users of the OsteoAnalyzer.
- 5. PACKAGE RECEIVING AND OPENING PROCEDURES
- 5.1. The I-125 sources are also less than Type A quantities of radioactive material. Consequently, no radiation surveys are required on receipt of the package. When shipped from the manufacturer, the packages carry a WHITE-I radioactive label, indicating that radiation levels on the surface are less than 0.5 mR/hr.
- 5.2. Open the outer shipping container. Open the inner shipping container with the brass source capsule. Take a canvas wipe and

wipe the brass source capsule. Analyze the wipe to verify there is no removable contamination greater than 200 dpm/100 cm .

- 5.3. Verify the serial number on the source against the serial number on the shipping documents. Log the receipt of the source into the source receipt log.
- 5.4. Leave the source in the original shipping container until it is actually installed in the analyzer.

6. SOURCE REPLACEMENT PROCEDURES

- 6.1. Remove the outer cover of the scanner unit. Using the key for the source compartment, unlock and remove the cover from the source compartment.
- 6.2. Unscrew the source from the receptacle in the source compartment. Immediately screw on the brass cap on the source. Make sure the end of the source capsule with the threads is always pointed away from you when the cap is not on.
- 6.3. Place the source in the shipping container to be returned to the manufacturer.
- 6.4. Remove the new brass source capsule with the brass cap attached from the shipping container. Unscrew the cap from the source and screw the source into the receptacle in the source compartment. Make sure the end of the source capsule with the threads is always pointed away from you when the cap is not on.
- 6.5. Using the key, lock the source compartment cover in place. Remove the key and store it in a secure location.
- 6.6. Replace the cover on the scanner unit.

7. SOURCE PACKAGING AND SHIPPING PROCEDURES

- 7.1. Place the source with the cap tightly screwed on in the foam insert from the original shipping container.
- 7.2. Place the foam insert in the original inner container (metal can) and tape the lid on the can with fabric-backed tape.
- 7.3. Place the metal can in the original outer shipping box and tape the box closed with security tape.
- 7.4. Remove old shipping labels, packing slips, and other old labels from the box. Make sure the words "RADIOACTIVE MATERIAL", "TYPE 'A' PACKAGE", "I.A.E.A. C.T.C-12B25", and the manufacturer's name and address are still clearly legible on the box.

70188

- 7.5. Place two new RADIOACTIVE WHITE-I labels over the old ones on the box. Enter I-125 as the contents. Calculate and enter the activity of the source.
- 7.6. Place a shipping label on the box with the name and address of the facility shipped from and shipped to.
- 7.7. Write or stamp the words "RADIOACTIVE MATERIAL, N.O.S." and "UN2982" on the box in letters at least 1/2" high.
- 7.8. Fill out the shipping papers for the shipment. The proper shipping name for the source is "Radioactive Material, N.O.S. (Iodine-125)" and the proper classification is "UN2982".

8. INVENTORY REQUIREMENTS

8.1. An inventory of all sources in use and in storage shall be made every six months. Records of the semi-annual inventories shall be kept.

9. EMERGENCY PROCEDURES

- 9.1. The low energy gamma and x-rays emitted from the I-125 source are completely absorbed by the brass source holder.
- 9.2. If for any reason the source is dropped when the cap is off, pick up the source by the end opposite the threaded end, being careful not to point the hole from the source window towards you. Pick up the brass source holder cap in your other hand and screw it on the source holder. This will totally shield any radiation coming from the source.


10. DUTIES AND RESPONSIBILITIES

- 10.1. The authorized users will be responsible for:
- 10.1.1. Receipt of sources and logging in the source receipt log.
- 10.1.2. Storage of sources received in the radioactive materials storage area.
- 10.1.3. Source replicement in the OsteoAnalyzer.
- 10.1.4. Packaging of sources for shipping and delivering to a carrier for shipment to the manufacturer.
- 10.1.5. Leak testing of sources in use over six months.

- 10.2. The Radiation Safety Officer will be responsible for the following:
- 10.2.1. Assuring that byproduct materials possessed under the license conform to the materials listed on the license.
- 10.2.2. Assuring that use of the device is only by individuals authorized by the license.
- 10.2.3. Assuring that all users wear personnel monitoring equipment when required.
- 10.2.4. Assuring that the sources are properly secured against unauthorized removal at all times when not in use.
- 10.2.5. Serving as a point of contact to give assistance in case of an emergency, and assuring that proper authorities are notified in case of an emergency.
- 10.2.6. Assuring that the terms and conditions of the license are met and that required records are periodically reviewed for compliance with NRC regulations and license conditions.

WASTE MANAGEMENT

- 1. Sources that have decayed below an acceptable level will be removed from the bone mineral analyzer and stored in a locked storage area.
- The storage area will be posted with a "CAUTION -RADIOACTIVE MATERIALS" sign.
- When sources are transferred to the source manufacturer for final disposal, the disposal shall be noted on the receipt/disposal log.
- 4. Sources will be returned to the manufacturer in the original shipping containers they were shipped in. The requirements of 10 CFR 49 shall be followed with regards to packing, labelling, marking, and surveying of the package and filling out the shipping documents.



U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

FULL NAME George S. Boren, M.D. STREET ADDRESS St. Mark's Hospital 1200 East 3900 South CITY | STATE | ZIP CODE Salt Lake City | Utah 84117

KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

- Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

ISOTOPE CONDITIONS DIAGNOSED OR TREATED A DIAGNOSIS OF THYROID FUNCTION DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME 1-131 LIVER FUNCTION STUDIES FAT ABSORPTION STUDIES 1-125 PAT ABSORPTION STUDIES SO OTHER 1-129 DETECTION OF THROMBOSIS 1-131 THYROID IMAGING Se-75 PANCREAS IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING TOTHER BRAIN IMAGING GARDIAC IMAGING TOTHER BRAIN IMAGING THYROID IMAGING TOTHER BRAIN IMAGING TOTHER TOTH		2. CLINICAL TRAINING AND	1	
DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME 1-131 LIVER FUNCTION STUDIES 1-125 FAT ABSORPTION STUDIES 57 IN VITRO STUDIES 50 OTHER 1-125 DETECTION OF THROMBOSIS 1-131 THYROID IMAGING 24 THYROID IMAGING 35 THYROID IMAGING 37 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 THAILIUM 201 Cardiar 50			PERSONAL PARTICIPATION	(Additional information or comments may be submitted in duplicate on separate sheets.)
DETERMINATION OF BLOOD AND BLOOD AND BLOOD PLOWS TUDIES 1-131 LIVER FUNCTION STUDIES 1-125 FAT ABSORPTION STUDIES 57 IN VITRO STUDIES 50 OTHER 1-126 DETECTION OF THROMBOSIS 1-131 THYROID IMAGING THYROID IMAGING TO STUDIES SEPERATE SIMAGING TO STUDIES TO PANCREAS IMAGING TO STUDIES TO PANCREAS IMAGING THYROID IMAGING TO STUDIES AND TO STUDIES OTHER BRAIN IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING TO STUDIES AND TO STUDIES AND TO STUDIES OTHER BRAIN IMAGING TO STUDIES AND THYROID IMAGING THYROID IMAGING TO SALIVARY GLAND IMAGING SALIVARY GLAND IMAGING TO SHOOD POOL IMAGING TO SHOULD		DIAGNOSIS OF THYROID FUNCTION	24	
FAT ABSORPTION STUDIES 1-123 KIDNEY FUNCTION STUDIES 50 OTHER 1-125 DETECTION OF THROMBOSIS 1-131 THYROID IMAGINS 24 FAT ABSORPTION STUDIES 50 OTHER 1-125 DETECTION OF THROMBOSIS TO RAM MAA VENCYRUM THYROID IMAGINS 24 THYROID IMAGINS Se-75 PANCREAS IMAGING YD-169 CISTERNOGRAPHY ID-161 Z Xe-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING CARDIAC IMAGING THYROID IMAGING SALIVARY GLAND IMAGING THYROID IMAGING SALIVARY GLAND IMAGING TC-99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 THAILUM 201 Cardian 50			Toyan .	
FAT ABSORPTION STUDIES 1-123 IN VITRO STUDIES OTHER 1-125 DETECTION OF THROMBOSIS 1-131 THYROID IMAGINS 24 THYROID IMAGINS Se-75 PANCREAS IMAGING YD-169 CISTERNOGRAPHY TID-111 ZE-113 BRAIN IMAGING CARDIAC IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING THYROID IMAGING SALIVARY GLAND IMAGING SALIVARY GLAND IMAGING TO-99m BLOOD POOL IMAGING TO-99m BLOOD POOL IMAGING TO-99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING TO-99m LIVER AND SPLEEN IMAGING TO-90m LIVER AND SPLEEN IMAGING TO-90m LIVER AND SPLEEN IMAGING TO-90m		LIVER FUNCTION STUDIES	1 FR P. (220)	Tourn hepatobeliary 8
INVITAD STUDIES 50 OTHER 1-125 DETECTION OF THROMBOSIS TO ARM MAA VENCY VAIM THYROID IMAGING 24 1-131 THYROID IMAGING 24 P-32 EYE TUMOR LOCALIZATION Se-75 PANCREAS IMAGING YD-169 CISTERNOGRAPHY TO TO111 2 Xe-133 PULMONARY FUNCTION STUDIES SO OTHER BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 37 THYROID IMAGING 37 THYROID IMAGING 34 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 THAILUM 201 Cardiar 50		FAT ABSORPTION STUDIES		0
IN VITRO STUDIES OTHER 1-125 DETECTION OF THROMBOSIS 1-131 THYROID IMAGING P-32 EYE TUMOR LOCALIZATION Se-75 PANCREAS IMAGING Yb-169 CISTERNOGRAPHY TO ID-1111 2 Xe-133 PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING CARDIAC IMAGING THYROID IMAGING SALIVARY GLAND IMAGING TC-99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 TNAILLUM 201 Cardiaz 50		KIDNEY FUNCTION STUDIES	57	
1-125 DETECTION OF THROMBOSIS 1-131 THYROID IMAGING 24 Thrown & SCINTIGRAN 8-75 PANCREAS IMAGING Yb-169 CISTERNOGRAPHY DI2-111 2 Xe-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING CARDIAC IMAGING TC-99m BLOOD POOL IMAGING TC-99m BLOOD POOL IMAGING TC-99m BLOOD POOL IMAGING TC-99m LIVER AND SPLEEN IMAGING LIVER AND SPLEEN IMAGING LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 Nalliun 201 Cardian 50		IN VITRO STUDIES	50	
P.32 EYE TUMOR LOCALIZATION Se-75 PANCREAS IMAGING Yb-169 CISTERNOGRAPHY TO ID:-111 2 Xe-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 37 THYROID IMAGING 39 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 TAUILIAN 201 Cardian 50	OTHER		Barrier I de	
P.32 EYE TUMOR LOCALIZATION Se-75 PANCREAS IMAGING Yb-169 CISTERNOGRAPHY TO ID:-111 2 Xe-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 37 THYROID IMAGING 39 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 TAUILIAN 201 Cardian 50	1-125	DETECTION OF THROMBOSIS		To gam MAA Vencyram 6
P-32 EYE TUMOR LOCALIZATION Se-75 PANCREAS IMAGING YD-169 CISTERNOGRAPHY DE-111 2 XE-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES OTHER BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 3 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 TO MAIITUM 201 Cardian 50 IMAIITUM 201 Cardian 50		A CONTRACTOR OF THE PROPERTY O	24	+ Thomas scrange
Yb-169 CISTERNOGRAPHY TO ID-111 2 Xe-133 BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES SO OTHER BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 3 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 TAUITUM 201 Cardiar 50			1144 451	
TC-99m BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES SO OTHER BRAIN IMAGING CARDIAC IMAGING THYROID IMAGING SALIVARY GLAND IMAGING TC-99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING LUNG IMAGING 50 Nallun 201 Cardian 50	Se- 75	PANCREAS IMAGING		
DTHER BRAIN IMAGING CARDIAC IMAGING THYROID IMAGING SALIVARY GLAND IMAGING TC-99m BLOOD POOL IMAGING TUVER AND SPLEEN IMAGING LUNG IMAGING 50 TABLE SECTION 145 LUNG IMAGING 50 TABLE SECTION 145 LUNG IMAGING 50 TABLE SECTION 145	Yb-169	CISTERNOGRAPHY & In-III	2	
BRAIN IMAGING 45 CARDIAC IMAGING 37 THYROID IMAGING 3 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 Nallium 201 Cardian 56	Xe-133		50	
CARDIAC IMAGING 37 THYROID IMAGING 3 SALIVARY GLAND IMAGING 34 PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 Nallium 201 Cardian 50	OTHER			
THYROID IMAGING SALIVARY GLAND IMAGING Tc.99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING LUNG IMAGING 50 Nallun 201 Cardiaz 50		BRAIN IMAGING	45	
SALIVARY GLAND IMAGING Tc-99m BLOOD POOL IMAGING PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING LUNG IMAGING 50 Nallun 201 Cardiar 50		CARDIAC IMAGING	37	
PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING LUNG IMAGING 50 Nallun 201 Cardiaz 50		THYROLD IMAGING	3	
PLACENTA LOCALIZATION LIVER AND SPLEEN IMAGING LUNG IMAGING 50 Nallun 201 Cardiaz 50		SALIVARY GLAND IMAGING		
LIVER AND SPLEEN IMAGING 145 LUNG IMAGING 50 Hallium 201 Cardian 50	Tc-99m	BLOOD POOL IMAGING	34	
LUNGIMAGING 50 hallium 201 cardiar 50		PLACENTA LOCALIZATION		
		LIVER AND SPLEEN IMAGING	145	
BONE IMAGING 160		LUNG IMAGING	50	hallun 201 Cardiar 50
		BONE IMAGING	160	

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS [Additional information or comments may be submitted in duplicate on separate sheets.]
A	8	С	0
P.32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA. LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
1-131	TREATMENT OF THYROID CARCINOMA		
1.131	TREATMENT OF HYPERTHYROIDISM		
Au- 198	INTRACAVITARY TREATMENT		
Co-60	INTERSTITIAL TREATMENT		
Or C+137	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	50	
Sn-113/ in-113m	GENERATOR		
Tc-99m	REAGENT KITS	50	
4. THE T	RAINING AND EXPERIENCE INDICATED BTAINED UNDER THE SUPERVISION OF	ABOVE 6 PRECEPT	CORSSIGNATURE (Wes Every Haines MI)
D	or Paul Brown	V	
and c. MAIN	Portland Velevan Admin	Hosps Ja	mes Ernest Haines MI)

3181 SW Sam Jackson Park Road Portland oregen 9770

8. DATE

11-30-83

ORE- 0013-1 NRC FORM 313M SUPPLEMENT B (9-81)

NRC FORM 313M SUPPLEMENT A U.S. NUCLEAR REGULATORY COMMISSION (9-81) TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER 1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER STATE OR TERRITORY IN WHICH LICENSED TO St. Mark's Hospital PRACTICE MEDICINE 3. CERTIFICATION SPECIALTY BOARD CATEGORY MONTH AND YEAR CERTIFIED A American Board of Radiology Diagnostic Radiology June 1980 4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES TYPE AND LENGTH OF TRAINING LECTURE! SUPERVISED FIELD OF TRAINING LOCATION AND DATE(S) OF TRAINING LABORATORY LABORATORY A B COURSES EXPERIENCE (Hours) (Hours) University of Oregon Health a. RADIATION PHYSICS AND Sciences University 40 40 INSTRUMENTATION Portland, Oregon 1976-1980 b. RADIATION PROTECTION 12 c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT 10 OF RADIOACTIVITY d RADIATION BIOLOGY 26 . RADIOPHARMACEUTICAL 22 10 CHEMISTRY 5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience) ISOTOPE MAXIMUM AMOUNT DURATION OF EXPERIENCE WHERE EXPERIENCE WAS GAINED TYPE OF USE SEE CLINICAL EXPERIENCE

INSTRUMENTATION

1. Survey Meters

- A. Manufacturer's name: Picker Nuclear Manufacturer's model number: 655-186 Number of instruments available: 1 Minimum range: 0 to 0.2 mR/hr Maximum range: 0 to 2000 mR/hr
- B. Manufacturer's name: Victoreen Instrument Division Manufacturer's model number: 6A Number of instruments available: 1 Minimum range: 0 to 300 cpm and 0 - 0.5 mR/hr Maximum range: 0 to 30.000 cpm and 0 - 50 mR/hr

2. Dose Calibrators

- A. Manufacturer's name: Radx Lanufacturer's model number: Mark V
- B. Manufacturer's name: Capintec Manufacturer's model number: CRC 7

3. Diagnostic Instruments

Type of Instrument	Manufacturer's Name	Model No.	
Scintillation Camera	Siemens	ZLC 750S â Scintiview	
Scintillation Camera	Siemens	Pho/Gamma IV	
Gamma Well Counter	Searle	8725	
Thyroid Uptake Probe	Searle		
Automatic Well Counter	Abbott		
Automatic Gamma Counter	Abbott	ANZR	

Item 9-1 Date: 4/29/85

70188